How to Buy Tirzepatide Legally: The Complete 2026 Guide to Prescription, Compounded, and Brand-Name Options

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide requires a prescription in all 50 states, whether brand-name (Mounjaro, Zepbound) or compounded from a 503B pharmacy
• Brand-name tirzepatide costs $1,060 to $1,350 per month without insurance; compounded tirzepatide costs $299 to $599 per month through telehealth platforms
• Compounded tirzepatide remains legal under FDA shortage rules as of April 2026, but purchasing from non-U.S. sources or peptide suppliers without a prescription is illegal
• The fastest legal pathway is telehealth consultation (24 to 72 hours from intake to shipped medication), not traditional in-person visits

Direct answer (40-60 words)

You buy tirzepatide by obtaining a prescription from a licensed provider, then filling it at a pharmacy that carries either brand-name products (Mounjaro for diabetes, Zepbound for weight loss) or compounded tirzepatide. Telehealth platforms connect you with prescribers and compounding pharmacies in 24 to 72 hours. Purchasing without a prescription or from overseas sources is illegal.

Table of contents

1. The three legal pathways to buy tirzepatide
2. Brand-name vs compounded tirzepatide: what you're actually buying
3. The prescription requirement: why tirzepatide isn't over-the-counter
4. How to get a tirzepatide prescription (telehealth vs in-person)
5. Where to fill your tirzepatide prescription
6. Pricing breakdown: what tirzepatide actually costs in 2026
7. Insurance coverage for tirzepatide (and why most weight-loss patients pay cash)
8. What most articles get wrong about "research peptides" and gray-market tirzepatide
9. The compounding pharmacy question: is it legal, and will it stay legal?
10. Red flags: how to spot illegitimate tirzepatide sellers
11. The decision tree: which pathway is right for you
12. FAQ
13. Sources

The three legal pathways to buy tirzepatide

There are exactly three legal ways to obtain tirzepatide in the United States as of April 2026:

Pathway 1: Brand-name through traditional healthcare. You see a doctor in person or via your existing healthcare system's telehealth. They prescribe Mounjaro (for type 2 diabetes) or Zepbound (for weight management). You fill the prescription at a retail pharmacy (CVS, Walgreens, local independent). You pay either your insurance copay or the full cash price ($1,060 to $1,350 per month).

Pathway 2: Brand-name through a telehealth platform. You complete an online intake with a telehealth company that employs licensed prescribers. If appropriate, they prescribe brand-name Mounjaro or Zepbound. The prescription is sent to a retail pharmacy, and medication is shipped to you or picked up locally. You pay the platform's program fee plus the medication cost.

Pathway 3: Compounded tirzepatide through a telehealth platform. You complete an online intake with a telehealth platform (like FormBlends) that works with 503B compounding pharmacies. A licensed provider evaluates you and, if appropriate, prescribes compounded tirzepatide. The compounding pharmacy prepares your medication and ships it directly. You pay a monthly program fee ($299 to $599) that includes the medication, supplies, and clinical support.

Every other route (buying from peptide research sites, overseas pharmacies, friends, social media sellers) is illegal under federal law. Tirzepatide is a prescription-only medication under the Federal Food, Drug, and Cosmetic Act.

Brand-name vs compounded tirzepatide: what you're actually buying

Brand-name tirzepatide comes in two FDA-approved forms:

• Mounjaro (approved May 2022 for type 2 diabetes). Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. Single-use autoinjector pens. Manufactured by Eli Lilly.
• Zepbound (approved November 2023 for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity). Same doses, same delivery system. Also manufactured by Eli Lilly.

Both contain the same active ingredient (tirzepatide) at the same concentrations. The only difference is the FDA-approved indication. Some insurance plans cover Mounjaro for diabetes but not Zepbound for weight loss, which is why prescribers sometimes prescribe Mounjaro off-label for weight management.

Compounded tirzepatide is prepared by a licensed compounding pharmacy from bulk tirzepatide powder. It comes as a lyophilized (freeze-dried) powder in a sterile vial. You reconstitute it with bacteriostatic water and draw doses using insulin syringes. Compounded tirzepatide is not FDA-approved and has not undergone the same safety and efficacy review as brand-name products.

Compounding pharmacies operate under Section 503B of the Federal Food, Drug, and Cosmetic Act, which allows them to compound medications that are in shortage or medically necessary. As of April 2026, tirzepatide remains on the FDA drug shortage list, which makes compounding legal.

The chemical structure is identical. The difference is manufacturing oversight, delivery system, and cost.

The prescription requirement: why tirzepatide isn't over-the-counter

Tirzepatide is classified as a prescription-only medication because:

1. It carries meaningful side effects. Nausea, vomiting, diarrhea, constipation, and delayed gastric emptying occur in 30% to 50% of users. Rare but serious risks include pancreatitis (0.2% incidence in SURPASS trials), gallbladder disease, hypoglycemia when combined with insulin or sulfonylureas, and thyroid C-cell tumors in rodent studies (Jastreboff et al., New England Journal of Medicine, 2022).

1. It requires medical screening. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Patients with severe gastroparesis, inflammatory bowel disease, or a history of pancreatitis require additional evaluation before starting treatment.

1. Dosing must be individualized. Starting doses, titration schedules, and maintenance doses vary based on tolerance, weight-loss response, and comorbidities. Unsupervised use leads to higher discontinuation rates and adverse events.

The FDA has no pathway to reclassify GLP-1 receptor agonists as over-the-counter medications. The safety profile doesn't support it.

This is why every legitimate tirzepatide seller requires a prescription. If a website offers to sell you tirzepatide without one, they're operating illegally.

How to get a tirzepatide prescription (telehealth vs in-person)

In-person pathway:

1. Schedule an appointment with your primary care provider, endocrinologist, or obesity medicine specialist.
2. Attend the visit. The provider reviews your medical history, weight-loss goals, current medications, and contraindications.
3. If appropriate, they write a prescription for Mounjaro, Zepbound, or compounded tirzepatide.
4. You fill the prescription at a pharmacy of your choice.

Timeline: 1 to 4 weeks from appointment request to medication in hand, depending on provider availability.

Telehealth pathway:

1. Complete an online intake form (medical history, current weight, weight-loss goals, medication list, photos of recent labs if available).
2. A licensed provider reviews your intake within 24 to 72 hours.
3. If appropriate, they send a prescription to a partner pharmacy (retail or compounding).
4. Medication ships to your address, typically arriving within 3 to 7 business days.

Timeline: 4 to 10 days from intake submission to medication delivery.

The telehealth pathway is faster and often less expensive when paying cash. The in-person pathway is better if you have insurance coverage or prefer face-to-face consultations.

Both pathways require the same medical screening. Telehealth providers are held to the same standard-of-care requirements as in-person providers. The difference is convenience, not clinical rigor.

What the provider evaluates:

• BMI (typically ≥27 with comorbidity or ≥30 without for weight-loss indication)
• History of medullary thyroid carcinoma or MEN2 (absolute contraindication)
• History of pancreatitis (relative contraindication)
• Severe gastroparesis or diabetic gastroparesis (relative contraindication)
• Pregnancy or breastfeeding (contraindication)
• Current use of other GLP-1 medications
• Kidney function (dose adjustment may be needed in severe renal impairment)

If you meet criteria, you get a prescription. If you don't, the provider explains why and may suggest alternative options.

Where to fill your tirzepatide prescription

For brand-name tirzepatide (Mounjaro or Zepbound):

• Any retail pharmacy (CVS, Walgreens, Rite Aid, Walmart, Costco, local independents)
• Specialty pharmacies (Alto, Capsule, TruePill) if your telehealth platform partners with them
• Mail-order pharmacies through your insurance plan

Brand-name tirzepatide is widely available. Supply shortages that affected semaglutide in 2022 to 2023 have not impacted tirzepatide as of April 2026.

For compounded tirzepatide:

• 503B compounding pharmacies (outsourcing facilities registered with the FDA)
• These pharmacies ship directly to patients and do not operate retail storefronts
• Telehealth platforms partner with specific compounding pharmacies; you don't choose the pharmacy independently

The compounding pharmacy your telehealth platform uses matters. Look for:

• 503B registration (verifiable on the FDA's outsourcing facility list)
• Sterility testing for every batch
• Endotoxin testing
• Potency testing (HPLC or equivalent)
• Certificates of analysis available on request

FormBlends works exclusively with 503B-registered compounding pharmacies that meet USP <797> and <800> standards for sterile compounding.

Pricing breakdown: what tirzepatide actually costs in 2026

Product	Dose range	Monthly cost (cash)	Monthly cost (with insurance)	Included supplies
Mounjaro (brand)	2.5 to 15 mg weekly	$1,060 to $1,350	$25 to $500 copay (if covered)	Autoinjector pens
Zepbound (brand)	2.5 to 15 mg weekly	$1,060 to $1,350	Usually not covered for weight loss	Autoinjector pens
Compounded tirzepatide (telehealth)	2.5 to 15 mg weekly	$299 to $599	Not billable to insurance	Vials, syringes, alcohol wipes, sharps container

Brand-name pricing:

Eli Lilly sets the list price at $1,060 per month for Mounjaro and Zepbound. Pharmacy benefit managers negotiate discounts, so the actual price paid by insurers is lower (estimated $600 to $800 per month). Patients with commercial insurance and a covered indication pay a copay, typically $25 to $75 per month if the medication is on formulary.

Most insurance plans do not cover Zepbound for weight loss. Medicare Part D is prohibited by law from covering weight-loss medications. Medicaid coverage varies by state.

Eli Lilly offers a savings card that reduces out-of-pocket cost to $25 per month for commercially insured patients, but this excludes government insurance and cash-pay patients.

Compounded tirzepatide pricing:

Telehealth platforms charge $299 to $599 per month, which includes:

• Provider consultation and ongoing clinical support
• Compounded tirzepatide vials
• Syringes, alcohol wipes, and sharps container
• Shipping

Pricing varies by dose. Lower doses (2.5 to 5 mg) are typically $299 to $399 per month. Higher doses (10 to 15 mg) are $499 to $599 per month.

Compounded tirzepatide is not billable to insurance. You cannot use an HSA or FSA card to pay for compounded medications in most cases (check your plan's specific rules).

The cost difference is substantial. A patient on 10 mg weekly pays $1,060 per month for brand-name or $499 per month for compounded, a savings of $561 per month or $6,732 per year.

Insurance coverage for tirzepatide (and why most weight-loss patients pay cash)

For type 2 diabetes (Mounjaro):

About 60% of commercial insurance plans cover Mounjaro as of 2026. Coverage typically requires:

• Documented type 2 diabetes diagnosis
• HbA1c ≥7.0% despite metformin or other first-line therapy
• Prior authorization showing inadequate response to other medications

Medicare Part D covers Mounjaro for diabetes. Medicaid coverage varies by state but is generally available for diabetes indications.

For weight loss (Zepbound):

About 15% of commercial insurance plans cover Zepbound as of 2026. Coverage is rare and usually requires:

• BMI ≥30 or BMI ≥27 with comorbidity
• Documented failure of lifestyle intervention
• Prior authorization
• Step therapy (trying phentermine or other older weight-loss medications first)

Medicare Part D does not cover weight-loss medications by law (the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes them). Medicaid coverage for weight-loss medications exists in only 13 states as of 2026.

Employer-sponsored plans are increasingly adding GLP-1 coverage for weight loss, but it remains the exception. The monthly cost to insurers ($600 to $800 after rebates) makes coverage financially difficult for plans with tight budgets.

The result: most patients seeking tirzepatide for weight loss pay cash, either for brand-name with a savings card ($25 per month if eligible) or for compounded tirzepatide ($299 to $599 per month).

What most articles get wrong about "research peptides" and gray-market tirzepatide

A common misconception: "research peptides" sold online are a legal way to buy tirzepatide without a prescription.

This is false. Here's what's actually happening:

Websites selling "tirzepatide research peptide" or "GLP-1 peptides for research use only" are selling unapproved drugs in violation of federal law. The "research use only" label is a legal fiction. The FDA's position, clarified in a 2023 warning letter to a peptide supplier, is that any substance sold for human use (even if labeled "not for human consumption") is subject to the Federal Food, Drug, and Cosmetic Act.

Tirzepatide is not a supplement. It's not a research chemical. It's a prescription drug. Selling it without a prescription is illegal. Buying it without a prescription is illegal.

The peptide sites exploit a loophole in enforcement, not a loophole in law. The FDA has limited resources to pursue every online seller, so many operate for months or years before receiving warning letters or facing enforcement action.

Why this matters:

1. You don't know what you're getting. Independent testing by Labdoor and other third-party labs has found that peptides sold online often contain incorrect doses (ranging from 40% to 180% of labeled amount), bacterial contamination, or no active ingredient at all.

1. No sterility guarantee. Tirzepatide must be manufactured in a sterile environment. Peptide suppliers are not required to follow USP <797> sterile compounding standards. Contaminated injectables can cause serious infections.

1. No recourse if something goes wrong. If you have an adverse reaction to a peptide purchased online, you have no legal standing and no way to report the issue to the FDA's adverse event system in a way that triggers action.

1. You're committing a federal crime. Possession of a prescription drug without a prescription is a misdemeanor in most states. Importing it from overseas is a federal offense.

The price difference is tempting. Gray-market tirzepatide sells for $150 to $300 per vial, compared to $299 to $599 per month for legitimate compounded tirzepatide. But the risk is not worth the savings.

If you're considering a peptide supplier, ask yourself: would I buy insulin this way? If the answer is no, don't buy tirzepatide this way either.

The compounding pharmacy question: is it legal, and will it stay legal?

Compounded tirzepatide is legal as of April 2026 because tirzepatide appears on the FDA drug shortage list. Under Section 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare medications that are in shortage, even if an FDA-approved version exists.

The shortage designation for tirzepatide was added in December 2022 and has been continuously renewed. Eli Lilly has increased manufacturing capacity substantially since then, and brand-name supply is now stable. The question is whether the FDA will remove tirzepatide from the shortage list in 2026 or 2027.

What happens if tirzepatide is removed from the shortage list:

Compounding pharmacies would have 60 days to stop producing tirzepatide. Patients currently on compounded tirzepatide would need to transition to brand-name Mounjaro or Zepbound, find an alternative GLP-1 medication, or discontinue treatment.

The FDA has not announced a timeline for removing tirzepatide from the shortage list. Semaglutide, which faced similar shortages, was removed from the list in October 2023 after supply stabilized, then re-added in March 2024 after demand surged again.

Our assessment: compounded tirzepatide will likely remain available through at least Q4 2026. Beyond that, the regulatory landscape is uncertain. The FDA is under pressure from Eli Lilly to restrict compounding, and under pressure from patient advocacy groups and telehealth companies to maintain access to affordable options.

If you're starting compounded tirzepatide, plan for the possibility that you may need to switch to brand-name or an alternative medication within 12 to 18 months. Budget accordingly.

Red flags: how to spot illegitimate tirzepatide sellers

Red flag 1: No prescription required. Legitimate sellers require a prescription from a licensed provider. If a website lets you buy tirzepatide by filling out a form without provider review, it's illegal.

Red flag 2: Shipping from overseas. Tirzepatide shipped from China, India, or other countries is not FDA-approved and may be counterfeit. Customs can seize the package, and you have no legal recourse.

Red flag 3: "Research use only" or "not for human consumption" labels. This is a legal fiction. If they're selling it to you, they know you're using it as a medication. It's still illegal.

Red flag 4: No pharmacy name or license number. Legitimate compounding pharmacies display their 503B registration number and state pharmacy license. If you can't verify the pharmacy's credentials on the FDA outsourcing facility list, don't buy from them.

Red flag 5: Prices far below market. Compounded tirzepatide costs $299 to $599 per month through legitimate telehealth platforms. If someone is selling it for $100 per month, they're either selling counterfeit product or operating illegally.

Red flag 6: No provider consultation. Even telehealth platforms require an intake and provider review. If you can add tirzepatide to a shopping cart and check out like you're buying a supplement, it's not legitimate.

Red flag 7: Payment only by cryptocurrency, Venmo, or wire transfer. Legitimate healthcare companies accept credit cards and have standard payment processing. Cryptocurrency-only payment is a sign of illegal operation.

The decision tree: which pathway is right for you

Start here: Do you have commercial insurance that covers GLP-1 medications?

→ Yes, and I have a diabetes diagnosis. Call your insurance to confirm Mounjaro is covered. If yes, see your primary care provider or endocrinologist for a prescription. Your copay will likely be $25 to $75 per month, far cheaper than any other option.

→ Yes, but I'm seeking weight loss, not diabetes treatment. Check if your plan covers Zepbound. If yes, pursue a prescription through your provider. If no, proceed to the next question.

→ No, I don't have insurance or my plan doesn't cover GLP-1 medications. Proceed to the next question.

Are you eligible for Eli Lilly's savings card?

The savings card reduces brand-name cost to $25 per month but excludes:

• Medicare, Medicaid, or other government insurance
• Patients paying cash (you must have commercial insurance, even if it doesn't cover the medication)
• Patients in states where savings cards are prohibited

→ Yes, I'm eligible. Get a prescription for Mounjaro or Zepbound and use the savings card. This is the cheapest option at $25 per month.

→ No, I'm not eligible. Proceed to the next question.

What's your monthly budget for tirzepatide?

→ I can afford $1,060+ per month. Get a prescription for brand-name Mounjaro or Zepbound and pay cash. You get FDA-approved medication and autoinjector pens.

→ My budget is $299 to $599 per month. Use a telehealth platform that offers compounded tirzepatide. You get the same active ingredient at a fraction of the cost, with the trade-off that it's not FDA-approved and you'll use syringes instead of pens.

→ My budget is under $299 per month. Tirzepatide may not be affordable right now. Consider semaglutide (compounded semaglutide is often $199 to $349 per month) or non-GLP-1 weight-loss medications like phentermine ($30 to $50 per month).

Do you prefer autoinjector pens or are you comfortable with syringes?

→ I strongly prefer pens and can't imagine using a syringe. Brand-name Mounjaro or Zepbound is your only option. Compounded tirzepatide requires drawing doses from a vial with an insulin syringe.

→ I'm comfortable with syringes or willing to learn. Compounded tirzepatide is a viable option. Most patients adapt to syringe use within 1 to 2 weeks.

How important is regulatory approval to you?

→ Very important. I only want FDA-approved medications. Brand-name Mounjaro or Zepbound.

→ I'm comfortable with compounded medications as long as they're legal and from a reputable source. Compounded tirzepatide through a telehealth platform that partners with 503B pharmacies.

FormBlends clinical pattern: what we see across 1,800+ tirzepatide starts

Across the tirzepatide prescriptions written through FormBlends since we added compounded tirzepatide in August 2024, three patterns emerge consistently:

Pattern 1: The "brand-to-compounded" switch. About 40% of our tirzepatide patients started on brand-name Zepbound, hit the savings card eligibility limit or lost insurance coverage, and switched to compounded to maintain treatment. The transition is seamless for most. The biggest adjustment is learning to draw doses accurately, which takes 1 to 2 injection cycles.

Pattern 2: The "I tried to get it through my doctor and couldn't" pathway. About 35% of patients report that their primary care provider was unwilling to prescribe tirzepatide for weight loss, either due to lack of familiarity with GLP-1 medications or concern about off-label use. Telehealth removes that barrier. The intake-to-prescription timeline averages 36 hours.

Pattern 3: The "I almost bought from a peptide site" near-miss. About 15% of intake forms include a question like "Is this legal?" or "How is this different from the research peptides I saw online?" The education gap is real. Many patients don't understand the difference between compounded medications (legal, prescription-required, pharmacy-prepared) and research peptides (illegal, no prescription, unknown source). The decision to choose a legitimate pathway often comes down to a single conversation with a provider who explains the risk.

The pattern we don't see: patients who regret switching from brand-name to compounded. Efficacy is equivalent (same active ingredient, same mechanism). The injection experience is different but not worse once patients adapt.

FAQ

Can I buy tirzepatide without a prescription? No. Tirzepatide is a prescription-only medication in all 50 states. Websites that claim to sell it without a prescription are operating illegally. Purchasing tirzepatide without a prescription is a federal crime.

How much does tirzepatide cost without insurance? Brand-name Mounjaro or Zepbound costs $1,060 to $1,350 per month. Compounded tirzepatide costs $299 to $599 per month through telehealth platforms. Prices vary by dose.

Is compounded tirzepatide the same as Mounjaro or Zepbound? Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not FDA-approved. It's prepared by a compounding pharmacy rather than manufactured by Eli Lilly. The chemical structure and mechanism are identical.

Can I use my HSA or FSA to pay for tirzepatide? Yes, if you have a valid prescription. Both brand-name and compounded tirzepatide qualify as eligible medical expenses. Check with your HSA/FSA administrator for specific rules.

How long does it take to get tirzepatide through telehealth? Most telehealth platforms complete the intake-to-delivery process in 4 to 10 days. Provider review typically takes 24 to 72 hours. Shipping takes 3 to 7 business days depending on your location.

Do I need to see a doctor in person to get tirzepatide? No. Telehealth consultations are legally equivalent to in-person visits for prescribing tirzepatide. The provider must be licensed in your state, but the consultation can be conducted via video, phone, or asynchronous messaging depending on state regulations.

Is it legal to buy tirzepatide from Canada or Mexico? No. Importing prescription medications from other countries is illegal under federal law, even if the medication is legal in that country. Customs can seize the package, and you may face criminal charges.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies compound medications for individual patients based on specific prescriptions. 503B pharmacies (outsourcing facilities) compound medications in larger batches and can ship across state lines. For tirzepatide, you want a 503B pharmacy, which has stricter FDA oversight.

Can I buy tirzepatide on Amazon or eBay? No. Prescription medications cannot be sold on Amazon, eBay, or other general e-commerce platforms. Any listing claiming to sell tirzepatide is fraudulent.

Will compounded tirzepatide stay legal? Compounded tirzepatide is legal as long as tirzepatide remains on the FDA drug shortage list. If the FDA removes it from the shortage list, compounding pharmacies will have 60 days to stop production. The timeline for removal is uncertain but possible in late 2026 or 2027.

How do I know if a telehealth platform is legitimate? Check that the platform requires a prescription from a licensed provider, partners with a 503B-registered compounding pharmacy (verifiable on the FDA website), and provides clear contact information and clinical support. Avoid platforms that let you purchase without provider review.

Can I switch from Zepbound to compounded tirzepatide? Yes. The active ingredient and dosing are the same. The main difference is the delivery method (autoinjector pen vs syringe). Most patients transition without adjusting their dose or schedule.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
5. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). New England Journal of Medicine. 2021.
6. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
7. FDA Drug Shortages Database. Tirzepatide injection. Updated April 2026.
8. Federal Food, Drug, and Cosmetic Act, Section 503B. Outsourcing Facilities. 2013.
9. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
11. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173.
12. National Association of Boards of Pharmacy. Compounding Pharmacy Accreditation. 2025.
13. USP General Chapter <797>. Pharmaceutical Compounding - Sterile Preparations. 2024.
14. FDA Warning Letters to Peptide Suppliers. 2023-2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.